Hospital
ST. Joseph Health Northern California, LLC
ST. Joseph Health Northern California, LLC was paid $2.67M by Medicaid between Jan 2018 and Apr 2019, across 119 billing codes. Its largest line is 99283, emergency room visit (moderate) — 46% of everything it billed.
33Billing provider infoST. JOSEPH HEALTH NORTHERN CALIFORNIA, LLC
FORTUNA, CA 95540
FORTUNA, CA 95540
33aNPI1285849026assigned 05/14/2007
33bProvider typeCritical Access Hospital
28Total paid$2.67M
24GClaims54,173
24DCodes billed119
24AFirst – last monthJan 2018 – Apr 2019
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#17 of 30
Median peer was paid$3.14M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,821 | $2.11M | |
| 2019 | 13,352 | $564K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 46% | 8,474 | 7,468 | $1.23M |
| 97139 | 6.4% | 4,283 | 875 | $170K | |
| 99201 | 4.7% | 940 | 568 | $126K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 897 | 837 | $85K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 208 | 207 | $84K |
| J3490 | Unclassified drugs | 3.0% | 5,780 | 2,879 | $82K |
| J2704 | Injection, propofol, 10 mg | 2.7% | 314 | 298 | $72K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 258 | 250 | $60K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 705 | 633 | $50K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 1,021 | 960 | $42K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 974 | 947 | $34K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 190 | 188 | $34K |
107 more codes
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.1% | 336 | $30K |
| 97750 | 1.1% | 321 | $29K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 78 | $29K |
| 80053 | Comprehensive metabolic panel | 1.0% | 2,803 | $28K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 308 | $27K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 210 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,625 | $25K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 539 | $24K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 483 | $23K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 704 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 475 | $18K |
| 59025 | Fetal non-stress test | <1% | 459 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 421 | $13K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 141 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 997 | $13K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 107 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 473 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 586 | $11K |
| 73562 | <1% | 260 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 97 | $9K |
| 84484 | <1% | 552 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 982 | $7K |
| 97799 | <1% | 190 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 282 | $7K |
| 80305 | <1% | 412 | $7K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 44 | $6K |
| 73030 | <1% | 147 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 324 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 279 | $6K |
| 80061 | Lipid panel | <1% | 560 | $5K |
| 83690 | <1% | 682 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 79 | $5K |
| 86003 | <1% | 48 | $5K | |
| 87040 | <1% | 200 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 570 | $5K |
| 72100 | <1% | 100 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 50 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 290 | $4K |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 24 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 28 | $4K |
| 73130 | <1% | 76 | $4K | |
| 83605 | <1% | 281 | $4K | |
| 90715 | <1% | 53 | $4K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $4K |
| 84439 | <1% | 559 | $4K | |
| 73110 | <1% | 90 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 197 | $3K |
| 87400 | <1% | 239 | $3K | |
| 73610 | <1% | 82 | $3K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 79 | $3K |
| 87186 | <1% | 358 | $3K | |
| 73630 | <1% | 84 | $3K | |
| 81001 | <1% | 931 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 33 | $3K |
| 85610 | <1% | 605 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 361 | $3K |
| 83735 | <1% | 404 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 83 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 83 | $2K |
| 81003 | <1% | 882 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 125 | $2K |
| 85027 | <1% | 284 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 83 | $2K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 12 | $2K |
| 83880 | <1% | 71 | $2K | |
| 87081 | <1% | 284 | $2K | |
| 82607 | <1% | 152 | $2K | |
| 87340 | <1% | 229 | $2K | |
| 76770 | <1% | 13 | $2K | |
| 86762 | <1% | 155 | $2K | |
| 86695 | <1% | 103 | $2K | |
| 86696 | <1% | 103 | $2K | |
| 85730 | <1% | 179 | $1K | |
| 86592 | <1% | 242 | $1K | |
| Z9725 | <1% | 25 | $1K | |
| 72040 | <1% | 25 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 24 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 106 | $990.98 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 99 | $958.33 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 116 | $951.20 |
| 85379 | <1% | 85 | $936.24 | |
| 82962 | <1% | 178 | $853.21 | |
| 82746 | <1% | 71 | $764.59 | |
| 86901 | <1% | 334 | $748.02 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 56 | $745.19 |
| 86900 | <1% | 334 | $718.61 | |
| 86850 | <1% | 298 | $670.46 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 65 | $653.21 |
| 86141 | <1% | 69 | $642.01 | |
| 86140 | <1% | 143 | $569.58 | |
| 83540 | <1% | 103 | $471.74 | |
| 83550 | <1% | 85 | $468.35 | |
| 81002 | <1% | 258 | $447.31 | |
| 87077 | <1% | 57 | $443.21 | |
| 87088 | <1% | 55 | $429.76 | |
| 87147 | <1% | 82 | $417.28 | |
| 85651 | <1% | 198 | $413.30 | |
| 82950 | <1% | 122 | $410.41 | |
| 86803 | <1% | 42 | $391.69 | |
| 85007 | <1% | 130 | $384.99 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 13 | $357.68 |
| 87070 | <1% | 39 | $308.28 | |
| 82570 | <1% | 45 | $221.31 | |
| 82550 | <1% | 13 | $142.74 | |
| 82728 | <1% | 13 | $125.58 | |
| 85652 | <1% | 39 | $75.27 | |
| 84481 | <1% | 13 | $60.53 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY FOR ENROLLMENT)
Parent organizationST. JOSEPH HEALTH SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.